Intervention not reported
Fatigue severity at the end of non‐pharmacological treatment (assessed by different fatigue scales) · people with stroke with fatigue
It is very uncertain whether the intervention changes fatigue severity at the end of non‐pharmacological treatment… (very low certainty).
1 finding from 1 review
Intervention not reported
Fatigue severity at the end of treatment (assessed by Fatigue Severity Scale) · people with stroke not necessarily having fatigue
1 finding from 1 review
Intervention not reported
Changes of fatigue scores from baseline to after treatment (assessed by energy/fatigue scale from the Medical Outcomes Study) · people with stroke not necessarily having fatigue
1 finding from 1 review
Intervention not reported
Proportion of participants with fatigue after treatment (assessed by the self report by participants) · people with stroke not necessarily having fatigue
It is very uncertain whether the intervention changes proportion of participants with fatigue after treatment (assessed by… (very low certainty).
1 finding from 1 review
Intervention not reported
Long‐term death or disability ( · patients with acute ischaemic stroke
The intervention may leads to lower long‐term death or disability ( (low certainty).
1 finding from 1 review
Intervention not reported
Short‐term death ( · patients with acute ischaemic stroke
1 finding from 1 review
Intervention not reported
Short‐term disability assessed by the Barthel Index ( · patients with acute ischaemic stroke
1 finding from 1 review
Intervention not reported
Severity of neurological deficits assessed by stroke scales for neurological deficits ( · patients with acute ischaemic stroke
1 finding from 1 review
Intervention not reported
Clinical improvement assessed by the China Stroke Scale ( · patients with acute ischaemic stroke
1 finding from 1 review
Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: composite of recurrent stroke (non‐fatal or… compared with medical therapy (low certainty).
1 finding from 1 review
Time‐to‐event analyses for composite of recurrent stroke or TIA · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for composite of recurrent stroke or TIA compared with medical therapy (low certainty).
1 finding from 1 review
Time‐to‐event analyses for composite of recurrent stroke or TIA stratified by the type of device studied ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for composite of recurrent stroke or TIA… compared with medical therapy (low certainty).
1 finding from 1 review
CI: Confidence interval;HR: hazard ratio · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Primary outcome measure: composite of recurrent stroke (non‐fatal or fatal) or transient ischemic attack (TIA) stratified by the type of device ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: composite of recurrent stroke (non‐fatal or… compared with medical therapy (low certainty).
1 finding from 1 review
Recurrent events: fatal or non‐fatal (same type of stroke, i.e. ischaemic or haemorrhagic) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: recurrent stroke (non‐fatal or fatal) compared with medical therapy (low certainty).
1 finding from 1 review
Primary outcome measure: recurrent stroke (non‐fatal or fatal) stratified by the type of device studied ‐ Amplatzer PFO occluder · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in primary outcome measure: recurrent stroke (non‐fatal or fatal)… compared with medical therapy (low certainty).
1 finding from 1 review
Death from any cause (secondary outcome 3) · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in secondary outcome: all‐cause mortality at the end of compared with medical therapy (low certainty).
1 finding from 1 review
Secondary outcome:total serious adverse events at the end of · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in secondary outcome:total serious adverse events at the end of compared with medical therapy (low certainty).
1 finding from 1 review
Secondary outcome: the incidence of atrial fibrillation · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC probably leads to higher secondary outcome: the incidence of atrial fibrillation compared with medical therapy (moderate certainty).
1 finding from 1 review
Time‐to‐event analyses for recurrent stroke · people with patent foramen ovale and a history of cryptogenic stroke or transient ischemic attack
TDC showed no clear difference in time‐to‐event analyses for recurrent stroke compared with medical therapy (low certainty).
1 finding from 1 review